Atezolizumab plus bevacizumab (A plus B) as first-line systemic therapy for advanced hepatocellular carcinoma (HCC): A multi-institution analysis of patient outcomes based on Child Pugh (CP) and ALBI liver function

被引：0
|
作者：
Storandt, Michael H.
Zemla, Tyler J.
Patell, Kanchi
Naleid, Nikolas
Gile, Jennifer
Tran, Nguyen H.
Chakrabarti, Sakti
Jin, Zhaohui
Mahipal, Amit
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA
[3] Univ Hosp Cleveland Med Ctr, Dept Internal Med, Cleveland, OH USA
[4] Mayo Clin, Div Med Oncol, Rochester, MN USA
[5] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA
[6] Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Dept Oncol, Cleveland, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4099
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Multiinstitutional cohort study of patient outcomes in Child-Pugh (CP) B liver function treated with atezolizumab plus bevacizumab (A plus B) for hepatocellular carcinoma (HCC).
    Mahipal, Amit
    Zemla, Tyler J.
    Patell, Kanchi
    Naleid, Nikolas
    Gile, Jennifer
    Jin, Zhaohui
    Tran, Nguyen H.
    Borad, Mitesh
    Chakrabarti, Sakti
    Storandt, Michael H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 50 - 50
  • [2] Outcomes of patients with Child-Pugh B and unresectable hepatocellular carcinoma undergoing first-line systemic treatment with sorafenib, lenvatinib, or atezolizumab plus bevacizumab
    Kikugawa, Chihiro
    Uchikawa, Shinsuke
    Kawaoka, Tomokazu
    Kinami, Takahiro
    Yano, Shigeki
    Amioka, Kei
    Naruto, Kensuke
    Ando, Yuwa
    Yamaoka, Kenji
    Tsuge, Masataka
    Kosaka, Yumi
    Ohya, Kazuki
    Mori, Nami
    Takaki, Shintaro
    Tsuji, Keiji
    Kouno, Hirotaka
    Kohno, Hiroshi
    Morio, Kei
    Moriya, Takashi
    Nonaka, Michihiro
    Aisaka, Yasuyuki
    Masaki, Keiichi
    Honda, Yohji
    Naeshiro, Noriaki
    Hiramatsu, Akira
    Aikata, Hiroshi
    Oka, Shiro
    ONCOLOGY, 2024, 102 (03) : 239 - 251
  • [3] Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
    Tada, Toshifumi
    Kumada, Takashi
    Hiraoka, Atsushi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Tada, Fujimasa
    Ohama, Hideko
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Kosaka, Hisashi
    Naganuma, Atsushi
    Matono, Tomomitsu
    Koizumi, Yohei
    Nakamura, Shinichiro
    Kaibori, Masaki
    Iijima, Hiroko
    Hiasa, Yoichi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 (08) : 1389 - 1397
  • [4] Advanced hepatocellular Carcinoma Atezolizumab plus Bevacizumab - new First-Line Therapy Standard
    Vetter, Christine
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (7-8) : 429 - 429
  • [5] Atezolizumab plus bevacizumab in Child-Pugh B advanced hepatocellular carcinoma patients
    Kim, Hyeyeong
    Cheon, Jaekyung
    Ha, Yeongjung
    Kim, Han Sang
    Kim, Chang Gon
    Kim, Ilhwan
    Kim, Chan
    Jung, Sang-Hoon
    Chon, Hong Jae
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [6] Atezolizumab plus bevacizumab in patients with child-Pugh B advanced hepatocellular carcinoma
    Cheon, Jaekyung
    Kim, Hyeyeong
    Kim, Han Sang
    Kim, Chang Gon
    Kim, Ilhwan
    Kang, Beodeul
    Kim, Chan
    Jung, Sanghoon
    Ha, Yeonjung
    Chon, Hong Jae
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [7] Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study
    Storandt, Michael H.
    Zemla, Tyler J.
    Patell, Kanchi
    Naleid, Nikolas
    Gile, Jennifer J.
    Tran, Nguyen H.
    Chakrabarti, Sakti
    Jin, Zhaohui
    Borad, Mitesh
    Mahipal, Amit
    ONCOLOGIST, 2024, 29 (11): : 986 - 996
  • [8] Regorafenib plus tislelizumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma (HCC)
    Chuang, Chienhuai
    Liu, Tsung-Hao
    Hsu, Meng-Chi
    Chang, Mo-Jung
    Cheng, Ann-Lii
    Hsu, Chiun
    ANNALS OF ONCOLOGY, 2023, 34 : S1398 - S1398
  • [9] Clinical value of atezolizumab plus bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.
    Vogel, Arndt
    Rimassa, Lorenza
    Sun, Hui-Chuan
    Abou-Alfa, Ghassan K.
    El-Khoueiry, Anthony B.
    Pinato, David James
    Daigl, Monica
    Alvarez, Javier Sanchez
    Orfanos, Panos
    Leibfried, Michael
    Zumofen, Marie-Helene Blanchet
    Gaillard, Vincent
    Merle, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Atezolizumab plus bevacizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis
    Giri, Suprabhat
    Angadi, Sumaswi
    Vaidya, Arun
    Singh, Ankita
    Roy, Akash
    Sundaram, Sridhar
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 228 - 235
12345